CORONA Remedies Q3FY26 Earnings Call Audio Recording Available
CORONA Remedies Limited has released the audio recording of their Q3 FY26 earnings call, which covers the financial results for the third quarter and nine months ended December 31, 2025. The recording is available on the company's website.
This is a standard post-earnings call procedure, providing access to a recording. It does not introduce new material information that would significantly impact the company's stock or operations.
The announcement is a routine update regarding the availability of an audio recording of a previous investor call and does not contain new financial information or significant corporate actions.
CORONA Remedies Limited has made the audio recording of their conference call with analysts and investors publicly available. This call discussed the unaudited financial results for the third quarter and the nine months that concluded on December 31, 2025.
The recording can be accessed on the company's official website at the following URL: https://www.coronaremedies.com/wp-content/uploads/2026/02/CORONA-Remedies-Q3FY26-Earnings-Call-Audio-Recording-03-Feb-2026.mp3.
This announcement follows up on a previous letter dated January 28, 2026, and complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.